Sofosbuvir plus rivabirin showed efficacy in reducing viral load in patients infected with hepatitis C who are considered unlikely to respond to treatment, data show. No deaths were recorded, and no patients stopped treatment due to adverse events. The findings appear in the Journal of the American Medical Association.

Related Summaries